Compliance, Regulatory Requirements 21 Jan 2025 compliance, regulation, pharmaceutical, controlled substances, drug enforcement, business application

⚖️Siegfried USA, LLC's Bulk Manufacturer Application Notice and Compliance Information

Siegfried USA, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Compliance, Healthcare 17 Jan 2025 regulations, administrative practice and procedure, reporting and recordkeeping requirements, healthcare compliance, telemedicine, controlled substances, prescription drugs, drug traffic control, va healthcare

🩺New VA Regulations on Telemedicine Prescriptions for Controlled Substances

This final rule authorizes Department of Veterans Affairs (VA) practitioners acting within the scope of their VA employment to prescribe controlled substances via telemedicine to a VA patient with whom they have not conducted an in-person medical evaluation. VA practitioners are permitted to prescribe controlled substances to VA patients if another VA practitioner has, at any time, previously conducted an in-person medical evaluation of the VA patient, subject to certain conditions.

Learn More
Compliance, Regulatory Requirements 17 Jan 2025 compliance, healthcare, regulations, chemicals, imports, administrative practice and procedure, reporting and recordkeeping requirements, exports, telemedicine, dea, controlled substances, prescription drugs, drug traffic control

💊New DEA Regulations on Telemedicine and Special Registration

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (the "Ryan Haight Act") generally requires an in-person medical evaluation prior to the issuance of a prescription of controlled substances but provides an exception to this in-person medical evaluation requirement where the practitioner is engaged in the "practice of telemedicine" within the meaning of the Ryan Haight Act. These proposed regulatory changes would establish a Special Registration framework and authorize three types of Special Registration. This proposed rulemaking also provides for heightened prescription, recordkeeping, and reporting requirements. DEA believes such changes are necessary to effectively expand patient access to controlled substance medications via telemedicine while mitigating the risks of diversion associated with such expansion. A summary of this rule may be found at https://www.regulations.gov/docket/DEA-2023-0029.

Learn More
Regulatory Compliance, Healthcare, Legal 10 Jan 2025 compliance, ohio, registration, medical license, dea, controlled substances